Suppr超能文献

洛拉替尼与其他间变性淋巴瘤激酶(ALK)酪氨酸激酶抑制剂(TKI)作为一线治疗ALK 阳性晚期非小细胞肺癌(NSCLC)的比较:系统评价和网络荟萃分析。

Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC).

机构信息

Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA, USA.

Lumanity, Sheffield, UK.

出版信息

Lung Cancer. 2024 Nov;197:107968. doi: 10.1016/j.lungcan.2024.107968. Epub 2024 Sep 29.

Abstract

BACKGROUND

Next-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) (alectinib, brigatinib, and lorlatinib) demonstrate superior progression-free survival (PFS) over chemotherapy or crizotinib as first-line (1L) treatment of ALK-positive advanced non-smallcell lung cancer (NSCLC).

METHODS

We conducted network meta-analyses (NMAs) comparing the relative efficacy of lorlatinib with other ALK TKIs in this indication. Evidence identified from a systematic literature review and subsequent updates formed the basis of our evidence. The primary analysis investigated PFS by independent review committee (IRC) in the intent-to-treat (ITT) population. Secondary outcomes included PFS among subgroups, intracranial time to progression (IC TTP), adverse events, and discontinuation due to adverse events. For each of the outcomes, Bayesian proportional hazards NMAs estimated the relative treatment effects. Additionally, we compared the design and results of eight published NMAs conducted for 1L ALK + advanced NSCLC to date.

RESULTS

We formed a network of 10 trials, allowing indirect treatment comparisons. Two trials directly compared alectinib (600 mg twice daily) to crizotinib and one trial directly compared lorlatinib to crizotinib. The results of the NMA show that the hazard ratios (95 % credible interval [CrI]) for ITT PFS IRC were 0.61 (95 % CrI: 0.39, 0.97) when comparing lorlatinib with alectinib (600 mg twice daily) and 0.57 (95 % CrI: 0.35, 0.93) when comparing lorlatinib with brigatinib. In the review of published NMAs, HRs for lorlatinib versus alectinib (600 mg twice daily) and brigatinib were compared. This comparison confirmed that each published NMA yielded similar results.

CONCLUSIONS

Our NMA analysis adds to existing findings and supplements data gaps from other published NMAs. Findings from eight published NMAs consistently supported lorlatinib as a clinically effective 1L treatment for ALK + advanced NSCLC patients compared to other TKIs.

摘要

背景

下一代间变性淋巴瘤激酶(ALK)酪氨酸激酶抑制剂(TKI)(阿来替尼、布加替尼和劳拉替尼)在作为 ALK 阳性晚期非小细胞肺癌(NSCLC)的一线(1L)治疗中,相较于化疗或克唑替尼,具有优越的无进展生存期(PFS)。

方法

我们进行了网络荟萃分析(NMAs),比较了劳拉替尼与其他 ALK TKI 在该适应证中的相对疗效。从系统文献回顾和随后的更新中确定的证据构成了我们证据的基础。主要分析通过独立审查委员会(IRC)在意向治疗(ITT)人群中评估 PFS。次要结局包括亚组的 PFS、颅内进展时间(IC TTP)、不良事件和因不良事件而停药。对于每个结局,贝叶斯比例风险 NMAs 估计了相对治疗效果。此外,我们还比较了迄今为止针对 1L ALK+晚期 NSCLC 进行的八项已发表 NMAs 的设计和结果。

结果

我们形成了一个包含 10 项试验的网络,允许进行间接治疗比较。两项试验直接比较了阿来替尼(600mg 每日两次)与克唑替尼,一项试验直接比较了劳拉替尼与克唑替尼。NMA 的结果显示,ITT PFS IRC 的危险比(95%可信区间[CrI])当比较劳拉替尼与阿来替尼(600mg 每日两次)时为 0.61(95% CrI:0.39,0.97),当比较劳拉替尼与布加替尼时为 0.57(95% CrI:0.35,0.93)。在对已发表 NMAs 的综述中,比较了劳拉替尼与阿来替尼(600mg 每日两次)和布加替尼的 HR。这一比较证实了每一项已发表的 NMA 都得出了相似的结果。

结论

我们的 NMA 分析增加了现有发现,并补充了其他已发表 NMAs 的数据空白。八项已发表 NMAs 的结果一致支持劳拉替尼作为一种临床有效的 1L 治疗方案,用于 ALK+晚期 NSCLC 患者,优于其他 TKI。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验